This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often identified by terms such as “anticipates,” “expects,” “intends,” “believes,” “estimates,” “may,” “will,” “potential,” “proposed,” “positioned,” and similar expressions, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this release include, but are not limited to: statements regarding the development, validation, performance, capabilities, advantages, and potential use of breath-based drug-testing technologies; the potential application of a DOT-like multi-drug breath-testing panel for recent-use detection; the performance, capabilities, and advantages of the Cannabix Breath Collection Unit, Breath Cartridge, and related collection technologies; anticipated demand for laboratory-based breath testing; the scalability and manufacturing of devices and cartridges; the commercialization of technologies described; the potential adoption of breath testing by workplace, forensic, criminal justice, treatment and recovery, clinical, law enforcement, school, or other safety-sensitive customers; expectations regarding additional testing, pilot programs, regulatory processes, customer validation, or commercial deployments; and the growth of market opportunities related to recent-use drug testing. Forward-looking statements involve numerous risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the statements. Such risks include, but are not limited to: the risk that scientific results, including validation or peer-reviewed findings, may not be replicated in broader use; that further research, customer validation, or regulatory review may require changes to testing methods, device design, collection protocols, or reporting practices; risks associated with product development, manufacturing scale-up, supply chain availability, or cost escalation; risks relating to commercialization, customer adoption, and market acceptance of new testing technologies; the ability of the Company and its partners to meet regulatory, forensic, evidentiary, workplace, or other applicable standards; risks associated with intellectual property protection and patent approvals; competitive technologies or market changes; general economic, financial, or operational risks; and risks that expected agreements, partnerships, pilot programs, customer deployments, or commercial adoption may not materialize or may be delayed. There is no assurance that any proposed products or testing methods will be successfully developed, manufactured at scale, accepted by regulators or customers, or achieve commercial adoption. There is no assurance that breath-based drug testing, including THC or DOT-like multi-drug breath testing, will be accepted as a legal standard, workplace standard, or evidentiary tool in any jurisdiction, or that validation work or peer-reviewed publication will result in commercial, regulatory, or legal benefits. Actual results and future events may differ materially from those anticipated. All forward-looking statements in this release are made as of the date hereof and are based on current expectations, estimates, and assumptions that involve significant business, scientific, regulatory, and economic uncertainties. The Company undertakes no obligation to update forward-looking statements except as required by law.